Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 13/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263243 | 0.94 | GAA (0.43) | GAAJAK2JAK1TYK2JAK3 | |
| SCHEMBL24263104 | 0.85 | MTNR1A (0.50) | GAAMTNR1AMTNR1BKDM5A | |
| SCHEMBL24263107 | 0.85 | MTNR1A (0.53) | GAAMTNR1AMTNR1BKDM5A | |
| SCHEMBL24263236 | 0.82 | GAA (0.41) | GAAMTNR1AMTNR1BKDM5A | |
| SCHEMBL24263216 | 0.82 | MTNR1A (0.44) | GAAMTNR1AMTNR1BKDM5A | |
| SCHEMBL24263127 | 0.80 | MTNR1A (0.46) | GAAMTNR1AMTNR1BKDM5A | |
| SCHEMBL24263080 | 0.80 | MTNR1A (0.55) | GAAMTNR1AMTNR1BKDM5APOLB | |
| SCHEMBL14886658 | 0.79 | GAA (0.49) | GAA | |
| SCHEMBL24263131 | 0.78 | HDAC8 (0.45) | GAA | |
| SCHEMBL24263134 | 0.78 | SMYD3 (0.39) | GAAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022040508-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |